STORM Therapeutics to Present Data on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at AACR Annual Meeting 2024

• Late breaking presentation on STORM’s METTL1 inhibitors, for the treatment of cancer, on 8 April 2024

26 March 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, will present late breaking data on STORM’s METTL1 inhibitors at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, held 5-10 April 2024.

The presentation entitled ‘First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer’ details the discovery of STORM’s first-in-class inhibitors of METTL1 tRNA methyltransferase and supporting evidence of its potential as a novel target for anti-cancer drugs.

Oliver Rausch, Chief Scientific Officer at STORM Therapeutics, said: “We are looking forward to presenting these data on our first-in-class METTL1 inhibitor at the AACR Annual Meeting. As we continue to develop our pipeline of therapies inhibiting RNA modifying enzymes, we are pleased with the progress we are making with METTL1 and are looking forward to advancing this candidate towards clinical development.”

Details of the late breaking poster presentation are as follow:

Poster Title: First-in-class inhibitors of the tRNA methyltransferase METTL1 for the treatment of cancer

Presenter: Alexandra Sapetschnig, Group Leader at STORM

Authors: Alexandra Sapetschnig¹, Beth Thomas¹, Eliza Yankova², Harry Fischl¹, Aleksandra Azevedo¹, Sarah Bucknell¹, Richard Fosbeary¹, Sapphire Sawyer¹, Sian Evans², Carmen Livi¹, Byron Andrews¹, Jack Rogan¹, Natalie Webster¹, Matthew Fyfe¹, Konstantinos Tzelepis², Oliver Rausch¹

Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2

Session Date and Time: Monday Apr 8, 2024 1:30 PM - 5:00 PM

Location: Poster Section 52

Poster Board Number: 17

Abstract Presentation Number: LB171

¹ Storm Therapeutics Ltd, Babraham Research Campus, Cambridge CB22 3AT, United Kingdom

² Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, United Kingdom

Late breaking abstracts will be available in an online itinerary planner here on the 5 April and will be available in on online only supplement to the AACR journal Cancer Research one month after the conference.